Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or e‑Newsletters.
This study assessed the comparative effectiveness of the Janus kinase1/2 inhibitors, tofacitinib and baricitinib, in patients with rheumatoid arthritis (RA) using a network meta-analysis and Cochrane systematic review of randomized controlled trials from 7 electronic databases and 2 trial registries.
This study explored the effects of sarilumab, an anti–interleukin-6Rα human monoclonal antibody, or placebo in combination with disease-modifying antirheumatic drugs (DMARDs) on fasting glucose and glycosylated hemoglobin (HbA1c) in diabetic and nondiabetic patients with rheumatoid arthritis (RA).
This retrospective analysis of the Optum One electronic health record (EHR) databases from various Integrated Delivery Networks (IDNs) and large group practices across the United States was conducted to examine the EHR reporting rates of several clinical measures among patients with rheumatoid arthritis (RA) who received a biologic or a targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
Using the Corrona Rheumatoid Arthritis (RA) registry, the current study sought to assess in routine clinical practice the effectiveness of tocilizumab monotherapy versus TNFi plus varying doses of MTX in patients with RA and prior exposure to TNFi.
An analysis compared patient-reported outcomes (PROs) from the ORAL Strategy trial, a phase 3b/4, triple-dummy, controlled trial that randomized patients with RA 1:1:1 to receive tofacitinib monotherapy 5 mg twice daily, tofacitinib 5 mg twice daily plus methotrexate (MTX), or subcutaneous adalimumab (40 mg every other week) plus MTX, with MTX dosed at 15 mg to 25 mg per week.
The objective of this post hoc analysis was to assess the proportion of patients who achieved clinical remission or low disease activity (LDA) by week 24 (TARGET) and week 52 (MOBILITY).
The analysis of the COMPACT trial sought to demonstrate noninferiority of tocilizumab alone versus tocilizumab plus methotrexate (MTX) in maintaining clinical response in patients with rheumatoid arthritis (RA) who achieve low disease activity (LDA) following treatment with tocilizumab plus MTX.
In the pivotal MONARCH study, subcutaneous (SC) sarilumab 200 mg plus placebo was administered every 2 weeks (q2w) versus adalimumab 40 mg SC plus placebo q2w.
Using 3 US healthcare claims databases, this population-based cohort study compared the CV risk associated with tocilizumab versus abatacept in patients with RA who newly started tocilizumab (n = 6237) or abatacept (n = 14,685).
Read Now